X0306 4 2017-04-17 0 0001539029 Clearside Biomedical, Inc. CLSD 0001592380 Thorp Clay C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300 ALPHARETTA GA 30005 1 0 1 0 Common Stock 2017-04-17 4 S 0 22000 7.43 D 4035364 I See Footnotes Common Stock 2017-04-18 4 S 0 44455 7.48 D 3990909 I See Footnotes Common Stock 2017-04-19 4 S 0 2030 7.37 D 3988879 I See Footnotes The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on September 16, 2016. Consists of (i) 647 shares sold by Hatteras NC Fund, LP ("Hatteras NC"), (ii) 8,437 shares sold by Hatteras Venture Partners III, LP ("HVP III"), (iii) 765 shares sold by Hatteras Venture Affiliates III, LP ("HVA III"), (iv) 1,364 shares sold by Hatteras Venture Partners IV, LP ("HVP IV") and (v) 10,787 shares sold by Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC"). This transaction was executed in multiple trades at prices ranging from $7.31 to $7.78, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC. The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Consists of (i) 1,307 shares sold by Hatteras NC, (ii) 17,048 shares sold by HVP III, (iii) 1,547 shares sold by HVA III, (iv) 2,756 shares sold by HVP IV and (v) 21,797 shares sold by HVP IV SBIC. This transaction was executed in multiple trades at prices ranging from $7.35 to $7.60, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon Consists of (i) 59 shares sold by Hatteras NC, (ii) 779 shares sold by HVP III, (iii) 71 shares sold by HVA III, (iv) 126 shares sold by HVP IV and (v) 995 shares sold by HVP IV SBIC. This transaction was executed in multiple trades at prices ranging from $7.34 to $7.45, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. /s/ Mark Ballantyne, Attorney-in-Fact for Clay Thorp 2017-04-19